uploads///PFE con

Pfizer and GlaxoSmithKline’s Consumer Health Business

By

Dec. 21 2018, Updated 1:30 p.m. ET

Pfizer’s business

Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018—compared to $2.5 billion during the same period in 2017, which reflects ~4% YoY (year-over-year) growth.

In the US market, Pfizer’s consumer health business’ net revenues during the first nine months of 2018 were $1.4 billion—compared to the first nine months of 2017, which reflects ~1% YoY growth. In international markets, Pfizer’s consumer health business’ net revenues during the first nine months of 2018 were to $1.27 billion—compared to $1.18 billion during the same period in 2017, which reflects ~8% YoY growth.

In the third quarter, Pfizer’s consumer health business reported revenues of $839.0 million—compared to $829.0 million in the third quarter of 2017, which represents ~1% YoY growth.

In the US and international markets, Pfizer’s consumer health segment generated revenues of $445.0 million and $394.0 million, respectively, which reflects an ~1% YoY decline and $4% YoY growth.

Article continues below advertisement

GlaxoSmithKline’s business

In the third quarter, GlaxoSmithKline’s (GSK) consumer health business reported revenues of 1.9 billion British pounds, which reflects 1% AER (annual equivalent rate) decline and 3% CER (constant exchange rate) growth.

GlaxoSmithKline’s consumer health business’ net revenues during the first nine months were 5.8 billion British pounds, which reflects ~2% AER decline and ~2% CER growth. GlaxoSmithKline’s oral health pushed the revenue growth, which was partially offset by a decline in Panadol sales.

In GlaxoSmithKline’s consumer health business, wellness, oral health, nutrition, and skin health generated revenues of 2.9 billion British pounds, 1.9 billion British pounds, 489.0 million British pounds, and 453.0 million British pounds, respectively, in the first nine months of 2018.

In the United States, Europe, and international markets, GlaxoSmithKline’s consumer health business generated revenues of 1.3 billion British pounds, 1.8 billion British pounds, and 2.6 billion British pounds, respectively.

Next, we’ll discuss what investors can expect from Pfizer and GlaxoSmithKline’s consumer health joint venture.

Advertisement

More From Market Realist

  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • Aol logo on office building,
    Company & Industry Overviews
    What We Know About Apollo Global Management, New Owners of AOL and Yahoo
  • Chick-fil-A sign
    Company & Industry Overviews
    Why It Only Costs $10K to Own a Chick-fil-A Location
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.